Cargando…
A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
In a study of chemotherapy as palliative treatment, 300 patients with untreated limited and extensive stage small cell lung cancer (SCLC), who did not have progressive disease after the first cycle of chemotherapy, were randomised to receive either regular 'planned' chemotherapy or chemoth...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977632/ https://www.ncbi.nlm.nih.gov/pubmed/1654983 |
_version_ | 1782135303642808320 |
---|---|
author | Earl, H. M. Rudd, R. M. Spiro, S. G. Ash, C. M. James, L. E. Law, C. S. Tobias, J. S. Harper, P. G. Geddes, D. M. Eraut, D. |
author_facet | Earl, H. M. Rudd, R. M. Spiro, S. G. Ash, C. M. James, L. E. Law, C. S. Tobias, J. S. Harper, P. G. Geddes, D. M. Eraut, D. |
author_sort | Earl, H. M. |
collection | PubMed |
description | In a study of chemotherapy as palliative treatment, 300 patients with untreated limited and extensive stage small cell lung cancer (SCLC), who did not have progressive disease after the first cycle of chemotherapy, were randomised to receive either regular 'planned' chemotherapy or chemotherapy given 'as required' (AR). All patients received the same chemotherapy: cyclophosphamide 1 gm m-2 i.v., vincristine 2 mg i.v., and etoposide 120 mg m-2 i.v. on day 1, and etoposide 100 mg b.d. orally on days 2 and 3. Planned chemotherapy was given regularly every 3 weeks. AR chemotherapy was given for tumour-related symptoms, or for radiological progression of disease. Both groups of patients were assessed every 3 weeks and a maximum of eight cycles of chemotherapy was given. A detailed quality of life assessment was made using daily diary cards. The median survival (MS) of patients given AR chemotherapy was not significantly worse than those receiving planned treatment [MS: Planned = 36 weeks (95% C.I. 32-40 weeks), AR = 32 weeks (95% C.I. 28-37 weeks) P = 0.960]. In the AR patients the median interval between treatments was 42 days. On average AR patients received half as much chemotherapy as planned patients. AR patients with a treatment-free interval (TFI) of more than 8 weeks between the first and second cycles of chemotherapy survived longer than those in whom this interval was less than 4 weeks; [MS: TFI greater than 8 = 47 weeks (95% C.I. 32-53 weeks); TFI less than 4 = 24 weeks (95% C.I. 17-34 weeks) P = 0.013]. Contrary to expectation, in the quality of life assessment the AR patients scored themselves as having more severe symptoms than patients receiving planned treatment. AR chemotherapy is a novel method of attempting to use cytotoxic drugs palliatively, which resulted in less drug treatment for approximately equivalent survival. However the palliative effect seen with as required treatment was less satisfactory than with planned chemotherapy. |
format | Text |
id | pubmed-1977632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1991 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19776322009-09-10 A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Earl, H. M. Rudd, R. M. Spiro, S. G. Ash, C. M. James, L. E. Law, C. S. Tobias, J. S. Harper, P. G. Geddes, D. M. Eraut, D. Br J Cancer Research Article In a study of chemotherapy as palliative treatment, 300 patients with untreated limited and extensive stage small cell lung cancer (SCLC), who did not have progressive disease after the first cycle of chemotherapy, were randomised to receive either regular 'planned' chemotherapy or chemotherapy given 'as required' (AR). All patients received the same chemotherapy: cyclophosphamide 1 gm m-2 i.v., vincristine 2 mg i.v., and etoposide 120 mg m-2 i.v. on day 1, and etoposide 100 mg b.d. orally on days 2 and 3. Planned chemotherapy was given regularly every 3 weeks. AR chemotherapy was given for tumour-related symptoms, or for radiological progression of disease. Both groups of patients were assessed every 3 weeks and a maximum of eight cycles of chemotherapy was given. A detailed quality of life assessment was made using daily diary cards. The median survival (MS) of patients given AR chemotherapy was not significantly worse than those receiving planned treatment [MS: Planned = 36 weeks (95% C.I. 32-40 weeks), AR = 32 weeks (95% C.I. 28-37 weeks) P = 0.960]. In the AR patients the median interval between treatments was 42 days. On average AR patients received half as much chemotherapy as planned patients. AR patients with a treatment-free interval (TFI) of more than 8 weeks between the first and second cycles of chemotherapy survived longer than those in whom this interval was less than 4 weeks; [MS: TFI greater than 8 = 47 weeks (95% C.I. 32-53 weeks); TFI less than 4 = 24 weeks (95% C.I. 17-34 weeks) P = 0.013]. Contrary to expectation, in the quality of life assessment the AR patients scored themselves as having more severe symptoms than patients receiving planned treatment. AR chemotherapy is a novel method of attempting to use cytotoxic drugs palliatively, which resulted in less drug treatment for approximately equivalent survival. However the palliative effect seen with as required treatment was less satisfactory than with planned chemotherapy. Nature Publishing Group 1991-09 /pmc/articles/PMC1977632/ /pubmed/1654983 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Earl, H. M. Rudd, R. M. Spiro, S. G. Ash, C. M. James, L. E. Law, C. S. Tobias, J. S. Harper, P. G. Geddes, D. M. Eraut, D. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. |
title | A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. |
title_full | A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. |
title_fullStr | A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. |
title_full_unstemmed | A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. |
title_short | A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. |
title_sort | randomised trial of planned versus as required chemotherapy in small cell lung cancer: a cancer research campaign trial. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977632/ https://www.ncbi.nlm.nih.gov/pubmed/1654983 |
work_keys_str_mv | AT earlhm arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT ruddrm arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT spirosg arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT ashcm arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT jamesle arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT lawcs arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT tobiasjs arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT harperpg arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT geddesdm arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT erautd arandomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT earlhm randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT ruddrm randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT spirosg randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT ashcm randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT jamesle randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT lawcs randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT tobiasjs randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT harperpg randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT geddesdm randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial AT erautd randomisedtrialofplannedversusasrequiredchemotherapyinsmallcelllungcanceracancerresearchcampaigntrial |